Full-Time

Executive Director

Therapeutic Area Safety Head, Cardiopulmonary

Posted on 11/1/2025

Deadline 11/21/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$226k - $391k/yr

+ Annual performance bonus

New Hope, PA, USA + 2 more

More locations: Bridgewater Township, NJ, USA | Horsham, PA, USA

Hybrid

Hybrid role; on-site presence in Raritan, NJ; Titusville, NJ; or Horsham, PA with remote days as per policy.

Category
Biology & Biotech (2)
,
Required Skills
Risk Management
Requirements
  • Physician (MD or equivalent) with 10 or more years of substantial Pharmaceutical Industry experience; clinical experience highly preferred.
  • Management experience in supervising a group of employees; demonstrated strong CREDO values; proven leadership skills; ability to thrive in a global, matrix environment.
  • Significant skills in clinical medicine and pharmacovigilance, including experience in post-marketing safety assessment
  • Demonstrated in-depth knowledge of principles of drug development, pharmacology, clinical trial methodology and design, medical monitoring of trials, assessment of drug risks and benefits, and safety assessment of drugs both on the market and in development
  • Proven track record in dealing with difficult safety issues, clinical safety data, interactions with global regulatory departments / agencies, and strong collaborative and networking skills.
  • Ability to successfully manage multiple critical issues simultaneously, critically evaluate data from multiple sources (eg, clinical trials, post-marketing environment, literature), and assess the strategic importance of the data
  • Ability to influence, negotiate and communicate with both internal and external customers.
  • Ability to develop, implement, communicate and influence policy and strategy internally and externally to the company
  • Fluent in written and spoken English
  • Excellent verbal and written communication skills, including formal presentation skills; good written skills as evidenced by publication and journal articles also desirable.
  • Knowledge of Good Clinical Practices and PV regulatory requirements, the conduct of clinical trials and for the appropriate contributions to regulatory filings, PV documents and risk management plans.
  • Working knowledge of the use of Microsoft suite of software products including Excel and Word
Responsibilities
  • Shape the safety strategy and risk management for all J&J Innovative Medicine products during drug development and post-marketing within CP Therapeutic Area
  • Partner closely and effectively with the Therapeutic Area, the Chief Safety Officer, the Chief Medical Officer J&J Innovative Medicine, the Qualified Person for Pharmacovigilance and other J&J IM R&D leaders and the other groups within GMS to proactively assess, respond and communicate safety concerns for products throughout the lifecycle
  • Connect with respective colleagues in the Clinical Therapeutic Area, Medical Affairs, Global Regulatory Affairs and the QPPV J&J IM for the implementation and compliance of post-marketing risk management commitments.
  • Provide oversight, medical expertise and leadership to the Therapeutic Area Medical Safety Officers, Safety Analysis Scientist Therapeutic Area Lead and their direct report Scientists for the end-to-end medical safety strategy of their assigned products
  • Grow, attract, retain, and develop top talent, and build teams to ensure organizational effectiveness, transparency, and communication.
  • Act ethically and responsibly to ensure patient safety is paramount
  • Provide leadership in regulatory authority interactions regarding safety and risk management for the Therapeutic Area, both written and verbal
  • Ensure compliance of drug safety activities and processes with global legislation and regulatory requirements
  • Provide input into key regulatory documents (e.g. Ad hoc reports, Health Hazard Evaluations, Clinical Overviews, PBRERS/PSURs, REMS/RMPs) and serve as the designated GMS leader and signatory on Therapeutic Area Labeling Committee
  • Coordinate safety topics within assigned Therapeutic Area that are presented to Medical Safety Council
  • In collaboration with other Therapeutic Area Safety Heads and TALs, ensure consistency of medical safety-related processes across Therapeutic Areas to ensure cohesive and coordinated approaches to best practices of clinical and post-marketing safety, working with QPPV J&J IM and other GMS functions to implement needed process improvements and maximize operational efficiencies
  • Serve as the Safety Representative on the Sponsor Committee for the Independent Data Monitoring Committee
  • Provide input on licensing and acquisition of pharmaceutical medicines
  • Support Global Safety Strategy & Risk Management Head in proactively managing of the annual budget and planned resource allocation of individuals to meet the portfolio objectives throughout the year.
  • Support regulatory inspection readiness, inspections, and CAPAs where relevant
Desired Qualifications
  • Written skills as evidenced by publication and journal articles
  • Experience presenting to technical and lay groups at public meetings
  • These items may also be considered desirable: Fluent in written and spoken English

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE